In-silico design, pharmacophore-based screening, and molecular docking studies reveal that benzimidazole-1,2,3-triazole hybrids as novel EGFR inhibitors targeting lung cancer.

MLA

Kumar, Sunil, et al. “In-Silico Design, Pharmacophore-Based Screening, and Molecular Docking Studies Reveal That Benzimidazole-1,2,3-Triazole Hybrids as Novel EGFR Inhibitors Targeting Lung Cancer.” Journal of Biomolecular Structure & Dynamics, vol. 42, no. 18, Nov. 2024, pp. 9416–38. EBSCOhost, https://doi.org/10.1080/07391102.2023.2252496.

APA

Kumar, S., Ali, I., Abbas, F., Rana, A., Pandey, S., Garg, M., & Kumar, D. (2024). In-silico design, pharmacophore-based screening, and molecular docking studies reveal that benzimidazole-1,2,3-triazole hybrids as novel EGFR inhibitors targeting lung cancer. Journal of Biomolecular Structure & Dynamics, 42(18), 9416–9438. https://doi.org/10.1080/07391102.2023.2252496

Chicago

Kumar, Sunil, Iqra Ali, Faheem Abbas, Anurag Rana, Sadanand Pandey, Manoj Garg, and Deepak Kumar. 2024. “In-Silico Design, Pharmacophore-Based Screening, and Molecular Docking Studies Reveal That Benzimidazole-1,2,3-Triazole Hybrids as Novel EGFR Inhibitors Targeting Lung Cancer.” Journal of Biomolecular Structure & Dynamics 42 (18): 9416–38. doi:10.1080/07391102.2023.2252496.